Intelligent Bio Solutions Begins Multi-Site Study for FDA 510(k) Submission
Intelligent Bio Solutions has initiated a multi-site method comparison study to support its FDA 510(k) submission for the Intelligent Fingerprinting Drug Screening System targeting opiate codeine. The company aims to validate accuracy and real-world performance by July 2026, with data collected from diverse participants across multiple clinical sites.
Tickers: $INBS